表紙
市場調査レポート

神経刺激:技術・世界市場

Neurostimulation: Technologies and Global Markets

発行 BCC Research 商品コード 298489
出版日 ページ情報 英文 137 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
神経刺激:技術・世界市場 Neurostimulation: Technologies and Global Markets
出版日: 2014年03月28日 ページ情報: 英文 137 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の神経刺激装置市場は2013年に38億米ドルに達し、今後はCAGR1.5%で拡大し、2018年に41億米ドルに達すると予測されています。

当レポートは、世界の神経刺激装置市場について調査し、市場代用、市場動向、疾患別の市場分析、市場影響因子の調査、新製品発売、現在の有望な治験および特許/技術パイプラインの評価、および主要企業のプロファイルなどを提供しており、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 神経刺激装置の概要

  • 市場動向(技術)および市場シェア(主要企業・参入レベル)
    • 慢性痛
    • 聴力損失
    • 過活動膀胱
    • てんかん
    • 下垂足
    • 消化器疾患
  • プラスの市場影響
    • 複数用途向けの神経刺激装置の受け入れの増加
    • 神経刺激治療が現在の治療オプションにかけている部分を埋める、もしくは現在の治療オプションと合わせて用いられる
  • マイナスの市場影響
    • 現在の装置リコール:神経刺激装置のリスク暴露
    • 新技術の進歩に向けた投資・資金
    • 新技術・全体的な市場受け理れの増加による製品取り扱い・埋め込みトレーニングの不足

第4章 神経刺激装置市場

  • 疼痛管理向け神経刺激
    • 慢性背痛
    • 慢性片頭痛
    • 腰椎術後疼痛症候群
    • 慢性難治性疼痛
  • 運動障害向け神経刺激
    • パーキンソン病
    • パーキンソン病を含む精神神経疾患
    • ジストニア
    • 本態性振戦
    • てんかん
    • 精神神経疾患向け神経刺激
    • 統合失調症
    • 強迫神経症(OCD)/トゥレット・シンドローム
    • アルツハイマー病(認知症)
    • 神経性無食欲症(摂食障害)
    • 気分障害(双極性障害・うつ病)
  • 脳卒中・外傷性脳損傷向け神経刺激
    • 脳卒中
    • 外傷性脳損傷
  • 心疾患向け神経刺激
    • 心不全
  • 消化器疾患向け神経刺激
    • 胃の運動障害
    • 胃不全まひ
    • 肥満
  • 尿・直腸障害向け神経刺激
    • 尿失禁
  • 感覚障害向け神経刺激
    • 聴力損失
    • 適応性神経刺激療法

第5章 企業プロファイル

図表リスト

目次
Product Code: PHM149A

The global neurostimulation devices market is expected to reach $3.8 billion in 2013 and $4.1 billion in 2018, with a compound annual growth rate (CAGR) of 1.5%.

This report provides:

  • An overview of the global market for neurostimulation devices, many of which currently are in clinical trials or undergoing development to treat a range of disorders, including epilepsy, obesity, Parkinson's disease, depression, sexual dysfunction, urinary tract disorders, and drug addiction
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
  • A focus on individual disorders and variety of neurostimulation options, which include deep brain stimulation, transcranial magnetic brain stimulation, spinal cord stimulation, vagal nerve stimulation, sacral nerve stimulation, occipital nerve stimulation, tibial nerve stimulation, gastric electrical stimulation, and closed-loop/responsive stimulation
  • Examination of positive market impacts, which include increasing acceptance of neurostimulation devices for multiple applications, an aging population market, and technological advancements; as well as negative impacts, which include current device recalls, risks of neurostimulation devices, and investment and funding for new technological advancements
  • Evaluations of new product launches, current promising clinical trials, and the patent/technological pipeline
  • Comprehensive company profiles of major players.

INTRODUCTION

Neurostimulation incorporates technological advancements from a variety of fields including science, medicine and bioengineering. The main goal through these technologies is to develop implantable electrical devices to improve the quality of human life and day-to-day human functioning. This involves the process of electrically inhibiting or activating the functioning of the peripheral, central or autonomic nervous systems. The earliest implantable neurostimulation devices were spinal cord stimulators and stimulators to treat cardiovascular disease. In the 1970s, deep brain stimulator devices were introduced. It was around this time that the U.S. Food and Drug Administration (FDA) required implantable devices to be regulated and compliable with patient safety measures. From the 1980s to today, neurostimulators have been mainly used to treat movement disorders. The neurostimulation device industry has seen rapid growth in the past decade. These technological advancements have not only led to improvements in existing neurostimulation devices, but they have also aided the development of the next generation of devices.

Neurostimulation devices are increasingly used for pain management. Each year it is estimated that over 100 million people globally suffer from chronic pain. Currently drug therapies are the primary treatment option; however, in the long run these therapies have proved to be ineffective. As a result, in the current neurostimulation industry devices are of increasing interest for treating chronic pain. Recently a large number of neurostimulation devices have begun clinical trials or are undergoing development to treat a range of disorders including: epilepsy, obesity, Parkinson's disease, depression, sexual dysfunction, cardiovascular disorders, movement disorders, gastrointestinal disorders, urinary tract disorders, sensory disorders and drug addiction. This opens up a wider market of applications for neurostimulation devices. This also points to the fact that a wide variety of clinical specialists, apart from neurosurgeons and neurologists, would be interested in applying the therapies enabled by neurostimulation.

Currently, the market is underdeveloped despite technological advances due to low medical acceptance and equally low consumer awareness. Patients still fear the prospect of having a foreign object implanted into their bodies. This is anticipated to change with the commercialization of technologically advanced neurostimulators, physician training, increased venture capital and government funding and considerably due to the expansion of health insurance to the underinsured and uninsured. It should be noted that even with the expansion of health insurance, often health insurance providers do not offer full reimbursement for neurostimulation devices.

This is due to some providers being ill-informed and not being fully clear on the concept of neurostimulation as a viable treatment option. It becomes a priority for leading medical device manufacturers and physicians to inform insurance providers about the benefits and success stories of neurostimulation devices. This will lead to the successful implementation of neurostimulation devices on the market from manufacturing to implantation and through patient therapy.

STUDY GOALS AND OBJECTIVES

This report, Neurostimulation, from BCC Research includes forecasted trends and sales through 2018. Current market leaders, new technologies and factors influencing low and high demand are discussed. Neurostimulation ranges from noninvasive to minimally invasive to fully invasive. Depending upon the application, various neurostimulation devices are currently on the market. This report is particularly focused on individual disorders and discusses a variety of neurostimulation options for each disorder-including deep brain stimulation, transcranial magnetic brain stimulation, spinal cord stimulation, vagal nerve stimulation, sacral nerve stimulation, occipital nerve stimulation, tibial nerve stimulation, gastric electrical stimulation and closed-loop/responsive stimulation. Finally, the report includes information about market share, new product launches, promising technologies and current clinical trials.

REASONS FOR DOING THE STUDY

As of 2011, the size of the neurostimulation market was estimated at 4.2 billion. This market serves a patient population with both sensory and motor neural deficits. Compared to other medical device markets, the neurostimulation market can still be considered as an emerging market. At this point in time, the exiting neurostimulation technologies of spinal cord stimulation, cochlear implants and vagal nerve stimulation are widely successful. The success of these technologies with current advances in imaging technologies can provide an increase in the number of clinical applications for neurostimulation devices. These applications will also increase with the establishment of specialized medical training and a patient population eligible to benefit from the neurostimulation devices.

In the past few years, these advances have led to the development of a large number of small start-up firms working on exciting new technologies. This has created a competitive market place. This report will provide the reader with an overview of neurostimulation devices available for treating individual disorders along with an overview of company profiles.

SCOPE OF REPORT

This report is a business tool that primarily will be helpful in examining trends in the market for neurostimulation devices. It begins with an overview of neurostimulation devices, key players, entry-level players, market trend analysis and factors influencing future incidence. It will also include market analysis by clinical disorder, including annual incidence, trend analysis and factors influencing future predicted surgical volume. Finally, the report will cover market share and information on key neurostimulation device manufacturers.

ANALYST CREDENTIALS

Minal Patel is a research scientist with 13 years of experience in the field of medical devices, tissue engineering, orthopedic research, neuroscience, materials and hearing research.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE A: DISTRIBUTION OF NEUROSTIMULATION DEVICES BY TYPE OF DISORDER CATEGORY 2012-2018 ($ MILLIONS)
  • SUMMARY FIGURE B: GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY 2012-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW OF NEUROSTIMULATION DEVICES

  • MARKET TRENDS (TECHNOLOGIES) AND MARKET SHARE (KEY PLAYERS AND ENTRY LEVEL)
    • CHRONIC PAIN
      • TABLE 1: MARKET SHARE OF CHRONIC PAIN DEVICE MANUFACTURERS ($ MILLIONS)
      • FIGURE 1: MARKET SHARE OF CHRONIC PAIN NEUROSTIMULATION DEVICE SALES IN 2012, BY MANUFACTURER (%)
      • TABLE 2: MARKET SHARE OF CHRONIC PAIN DEVICE MANUFACTURERS ($ MILLIONS)
    • HEARING LOSS
      • FIGURE 2: MARKET SHARE OF HEARING LOSS NEUROSTIMULATION DEVICE SALES IN 2012, BY MANUFACTURER (%)
      • TABLE 3: HEARING LOSS DEVICE GLOBAL MARKET DISTRIBUTION ($ MILLIONS)
      • TABLE 4: MANUFACTURERS OF HEARING LOSS DEVICES MARKET SHARE ($ MILLIONS)
    • OVERACTIVE BLADDER
      • TABLE 5: MANUFACTURERS OF OVERACTIVE BLADDER DEVICES MARKET SHARE IN NORTH AMERICA ($ MILLIONS)
    • EPILEPSY
      • TABLE 6: MARKET SHARE OF MANUFACTURERS OF EPILEPSY DEVICES ($ MILLIONS)
    • FOOT DROP
      • TABLE 7: MARKET SHARE OF MANUFACTURERS OF FOOT DROP DEVICES ($ MILLIONS)
    • GASTROINTESTINAL DISORDERS
      • FIGURE 3: SALES DISTRIBUTION OF DIABETES/OBESITY NEUROSTIMULATION DEVICES BY MANUFACTURER, 2012 (%)
      • TABLE 8: MARKET SHARE OF MANUFACTURERS OF DIABETES/OBESITY DEVICES, 2012 ($ MILLIONS)
      • Retinal Degeneration
  • POSITIVE MARKET IMPACT
    • INCREASING ACCEPTANCE OF NEUROSTIMULATION DEVICES FOR MULTIPLE APPLICATIONS
      • New Technological Advancements
    • NEUROSTIMULATION THERAPIES FILL THE VOID OR ARE USED IN CONJUNCTION WITH CURRENT TREATMENT OPTIONS
  • NEGATIVE MARKET IMPACT
    • CURRENT DEVICE RECALLS - EXPOSING RISKS OF NEUROSTIMULATION DEVICES
    • INVESTMENT AND FUNDING FOR NEW TECHNOLOGICAL ADVANCES
    • LACK OF PRODUCT HANDLING AND IMPLANTATION TRAINING DUE TO INCREASING NEW TECHNOLOGIES AND OVERALL MARKET ACCEPTANCE

CHAPTER 4 - MARKET FOR NEUROSTIMULATION DEVICES

  • NEUROSTIMULATION FOR PAIN MANAGEMENT
    • CHRONIC BACK PAIN
      • FIGURE 4: DISTRIBUTION OF CHRONIC BACK PAIN INJURY/ILLNESS REQUIRING DAYS MISSED FROM WORK, BY CONDITION (INCIDENCE RATE)
      • FIGURE 5: DISTRIBUTION OF SPRAINS, STRAINS AND TEARS REQUIRING ABSENCES FROM WORK, BY BODY PARTS INCLUDING BACK (%)
      • FIGURE 6: DISTRIBUTION OF BACK INJURY INCIDENT RATES BY AGE GROUP (INCIDENCE RATE)
      • FIGURE 7: DISTRIBUTION OF INCIDENCE RATES OF SORENESS INCLUDING BACK PAIN, BY AGE GROUP (INCIDENCE RATE)
      • TABLE 10: PREMARKET APPROVALS (PMA) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 11: PREMARKET NOTIFICATION (510K) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 12: CLINICAL TRIALS FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
    • CHRONIC MIGRAINE
      • FIGURE 8: DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS INCLUDING MIGRAINE AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS (%)
      • FIGURE 9: DISTRIBUTION OF MIGRAINE INCIDENCE RATES BY AGE GROUP (INCIDENCE RATE)
      • TABLE 13: CLINICAL TRIALS UNDERWAY FOR CHRONIC MIGRAINE-ASSOCIATED NEUROSTIMULATION DEVICES
    • FAILED BACK SURGERY SYNDROME
      • TABLE 14: PREMARKET APPROVALS (PMA) FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 15: CLINICAL TRIALS FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES
    • CHRONIC INTRACTABLE PAIN
      • TABLE 16: PREMARKET APPROVALS (PMA) FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 17: CLINICAL TRIALS FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 18: AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
  • NEUROSTIMULATION FOR MOVEMENT DISORDERS
    • PARKINSON'S DISEASE
      • FIGURE 10: GLOBAL PREVALENCE OF PARKINSON'S DISEASE ($ MILLIONS)
      • FIGURE 11: NUMBER OF DEATHS GLOBALLY DUE TO INDIVIDUAL
    • NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE (%)
      • FIGURE 12: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE (%)
      • FIGURE 13: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE (%)
      • FIGURE 14: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS (%)
      • FIGURE 15: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING PARKINSON'S DISEASE AS A PERCENTAGE OF TOTAL DALYS IN MALES (%)
      • FIGURE 16: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES (%)
      • FIGURE 17: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS (%)
      • TABLE 19: PREMARKET APPROVALS (PMA) FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 20: CLINICAL TRIALS FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 21: PATENTS FOR NEUROSTIMULATION AND PARKINSON'S APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013 (NUMBER)
    • DYSTONIA
      • TABLE 22 :PREMARKET APPROVALS (PMA) FOR DYSTONIA-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 23: CLINICAL TRIALS FOR DYSTONIA-ASSOCIATED DEEP NEUROSTIMULATION DEVICES
      • Patents
      • TABLE 24: NEUROSTIMULATION AND DYSTONIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013 (NUMBER)
    • ESSENTIAL TREMOR
      • TABLE 25: PREMARKET APPROVALS (PMA) FOR ESSENTIAL TREMOR-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 26: CLINICAL TRIALS FOR ESSENTIAL TREMOR-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 27: NEUROSTIMULATION AND ESSENTIAL TREMOR PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013 (NUMBER)
    • EPILEPSY
      • TABLE 28: DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS (%)
      • TABLE 29: DISTRIBUTION OF RANKINGS FOR EPILEPSY BY GLOBAL REGIONS. (RANK)
      • TABLE 30: GLOBAL PREVALENCE OF EPILEPSY (MILLIONS)
      • TABLE 31: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS IN MALES (%)
      • TABLE 32: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES (%)
      • FIGURE 18: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS (%)
      • TABLE 33: GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY (%)
      • TABLE 34: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY (%)
      • TABLE 35: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY (%)
      • TABLE 36: PREMARKET APPROVALS (PMA) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 37: PREMARKET NOTIFICATION (510K) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 38: CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES.
      • TABLE 39: CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED VAGAL NERVE NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 40: NEUROSTIMULATION AND EPILEPSY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013 (NUMBER)
    • NEUROSTIMULATION FOR NEUROPSYCHIATRIC DISORDERS
      • TABLE 41: DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP IN GLOBAL MALE POPULATION OF 2004 (%)
      • TABLE 42: DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP IN GLOBAL FEMALE POPULATION OF 2004 (%)
      • FIGURE 19: DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006 (%)
    • SCHIZOPHRENIA
      • TABLE 43: DISTRIBUTION OF RANKINGS FOR SCHIZOPHRENIA BY REGION, 2010 (RANKING)
      • FIGURE 20: GLOBAL PREVALENCE OF SCHIZOPHRENIA, 2004 (%)
      • FIGURE 21: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)
      • FIGURE 22: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%)
      • FIGURE 23: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS, 2006 (%)
      • TABLE 44: GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING SCHIZOPHRENIA 2010 (%)
      • TABLE 45: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, 2010 (%)
      • TABLE 46: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, 2010 (%)
      • TABLE 47: CLINICAL TRIALS FOR SCHIZOPHRENIA-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 48: NEUROSTIMULATION AND SCHIZOPHRENIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • OBSESSIVE-COMPULSIVE DISORDER (OCD)/TOURETTE SYNDROME
      • TABLE 49: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)
      • TABLE 50: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER. AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%)
      • TABLE 51: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER, AS A PERCENTAGE OF TOTAL DALYS (%)
      • TABLE 52: DISTRIBUTION OF DALYS FOR OCD IN MALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP, 2006 (%)
      • TABLE 53: DISTRIBUTION OF DALYS FOR OCD IN FEMALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP (%)
      • TABLE 54: CLINICAL TRIALS FOR OCD-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
      • TABLE 55: CLINICAL TRIALS FOR TOURETTE SYNDROME-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 56: NEUROSTIMULATION AND OCD PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • ALZHEIMER'S DISEASE (DEMENTIA)
      • TABLE 57: GLOBAL PREVALENCE OF ALZHEIMER'S DISEASE, 2006 (MILLIONS)
      • TABLE 58: RANKING OF MORTALITY DUE TO ALZHEIMER'S IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010 (RANK)
      • FIGURE 24: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)
      • TABLE 59: GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S, 2010 (%)
      • FIGURE 27: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006 (%)
      • TABLE 60: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, 2010 (%)
      • TABLE 61: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, 2010 (%)
      • TABLE 62: CLINICAL TRIALS FOR ALZHEIMER'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 63: NEUROSTIMULATION AND ALZHEIMER'S PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • ANOREXIA NERVOSA (EATING DISORDER)
      • TABLE 64: CLINICAL TRIALS FOR ANOREXIA NERVOSA-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 65: NEUROSTIMULATION AND ANOREXIA NERVOSA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • MOOD DISORDER (BI-POLAR DISORDER AND DEPRESSION)
      • Bipolar Disorder
        • TABLE 66: DISTRIBUTION OF RANKINGS FOR BIPOLAR DISORDER BY GLOBAL REGIONS, 2010
        • TABLE 67: GLOBAL PREVALENCE OF BIPOLAR DISORDER, 2004 (MILLIONS)
        • TABLE 68: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)
        • TABLE 69: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES (%)
        • TABLE 70: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS, 2006 (%)
        • TABLE 71: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, 2010 (%)
        • TABLE 72: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, 2010 (%)
        • TABLE 73: CLINICAL TRIALS FOR BIPOLAR DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 74: NEUROSTIMULATION AND BI-POLAR DISORDER PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
      • Depression
        • TABLE 75: DISTRIBUTION OF RANKINGS FOR DEPRESSION BY GLOBAL REGIONS, 2010
        • TABLE 76: GLOBAL PREVALENCE OF DEPRESSION, 2004 (MILLIONS)
        • FIGURE 28: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING DEPRESSION, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)
        • FIGURE 29: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING DEPRESSION, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%)
        • FIGURE 30: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION AS A PERCENTAGE OF TOTAL DALYS, 2006 (%)
        • TABLE 77: GLOBAL DEATHS DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010 (%)
        • TABLE 78: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010 (%)
        • TABLE 79: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010 (%)
        • TABLE 80: PRE-MARKET APPROVALS (PMA) FOR DEPRESSION ASSOCIATED NEUROSTIMULATION DEVICES
        • TABLE 81: CLINICAL TRIALS FOR DEPRESSION ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 82: NEUROSTIMULATION AND DEPRESSION PATENTS APPLIED AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
  • NEUROSTIMULATION FOR STROKE AND TRAUMATIC BRAIN INJURY
    • STROKE
      • TABLE 83: RANK OF MORTALITY DUE TO STROKE IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010
      • TABLE 84: GLOBAL PREVALENCE OF STROKE BY COUNTRY, 2004 (MILLIONS)
      • TABLE 85: CLINICAL TRIALS FOR STROKE-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 86: NEUROSTIMULATION AND STROKE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TRAUMATIC BRAIN INJURY
      • FIGURE 31: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION IN MALES AND FEMALES IN THE U.S., 1997 TO 2007 (NUMBER)
      • FIGURE 32: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007 (NUMBER)
      • FIGURE 33: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35-85 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007 (NUMBER)
      • FIGURE 34: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007 (NUMBER)
      • FIGURE 35: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35 TO 85 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007 (NUMBER)
      • TABLE 87: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY ETHNICITY IN THE U.S., FROM 1997 TO 2007
      • TABLE 88: CLINICAL TRIALS FOR TRAUMATIC BRAIN INJURY-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 89: NEUROSTIMULATION AND TRAUMATIC BRAIN INJURY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
  • NEUROSTIMULATION FOR CARDIOVASCULAR DISORDERS
    • HEART FAILURE
      • FIGURE 36: DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN MALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005 TO 2008 (%)
      • FIGURE 37: DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN FEMALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005-2008 (%)
      • FIGURE 38: GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP, INCLUDING CARDIOVASCULAR DISEASE, IN THE MALE POPULATION OF 2004 (%)
      • FIGURE 39: GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP, INCLUDING CARDIOVASCULAR DISEASE IN THE FEMALE POPULATION OF 2004 (%)
      • TABLE 90: CLINICAL TRIALS FOR HEART FAILURE-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 91: NEUROSTIMULATION AND HEART FAILURE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
  • NEUROSTIMULATION FOR GASTROINTESTINAL DISORDERS
    • GASTRIC DYSMOTILITY
      • TABLE 92: PRE-MARKET APPROVALS (PMA) FOR GASTRO-ESOPHAGEAL REFLUX DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 93: CLINICAL TRIALS FOR GASTRIC DYSMOTILITY-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 94: NEUROSTIMULATION AND GASTRIC DYSMOTILITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • GASTROPARESIS
      • TABLE 95: GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP INCLUDING DIABETES IN THE MALE POPULATION OF 2004 (%)
      • TABLE 96: GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP INCLUDING DIABETES, IN THE FEMALE POPULATION OF 2004 (%)
      • TABLE 97: PRE-MARKET APPROVALS (PMA) FOR GASTROPARESIS-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 98: CLINICAL TRIALS FOR GASTRIC DYSMOTILITY ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 99: NEUROSTIMULATION AND GASTROPARESIS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • OBESITY
      • TABLE 100: OBESITY IN MALES (>20 YEARS) BY GLOBAL REGION, 2008 (%)
      • TABLE 101: OBESITY IN FEMALES (>20 YEARS) BY GLOBAL REGION, 2008 (%)
      • TABLE 102: DISTRIBUTION OF OBESITY IN U.S. ADULTS (A) AND MALES (B) AS A PERCENTAGE OF TOTAL POPULATION BY AGE GROUP, 2009 TO 2010 (%)
      • TABLE 103: DISTRIBUTION OF OBESITY IN U.S. FEMALES AS A PERCENTAGE OF TOTAL POPULATION, ACCORDING TO AGE GROUP 2009 TO 2010 (%)
      • TABLE 104: PERCENTAGE OF OBESITY AMONG MALES (> 20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008
      • TABLE 105: PERCENTAGE OF OBESITY AMONG FEMALES (> 20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008 (%)
      • TABLE 106: DISTRIBUTION OF OBESITY IN U.S. ADOLESCENTS AND CHILDREN AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 (%)
      • TABLE 107: DISTRIBUTION OF OBESITY IN U.S. BOYS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 (%)
      • TABLE 108: DISTRIBUTION OF OBESITY IN U.S. GIRLS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 (%)
      • TABLE 109: CLINICAL TRIALS FOR OBESITY-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 110: NEUROSTIMULATION AND OBESITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
  • NEUROSTIMULATION FOR URINARY AND RECTAL DISORDERS
    • URINARY INCONTINENCE
      • TABLE 111: PRE-MARKET APPROVALS (PMA) FOR OVERACTIVE BLADDER DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 112: CLINICAL TRIALS FOR URINARY INCONTINENCE-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 113: NEUROSTIMULATION AND URINARY INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
      • Fecal Incontinence
        • TABLE 114: PREMARKET APPROVALS (PMA) FOR FECAL INCONTINENCEASSOCIATED NEUROSTIMULATION DEVICES
        • TABLE 115: CLINICAL TRIALS FOR FECAL INCONTINENCE ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 116: NEUROSTIMULATION AND FECAL INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
  • NEUROSTIMULATION FOR SENSORY DISORDERS
    • HEARING LOSS (COCHLEAR NERVE STIMULATION)
      • TABLE 117: DISTRIBUTION OF RANKINGS FOR HEARING LOSS BY REGION, 2010
      • TABLE 118: GLOBAL PREVALENCE OF MODERATE OR GREATER HEARING LOSS DISEASE, 2004 (MILLIONS)
      • TABLE 119: GLOBAL PREVALENCE OF MILD OR GREATER HEARING LOSS DISEASE, 2004 ($ MILLIONS)
      • TABLE 120: LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY, INCLUDING HEARING, LOSS IN MALES, 2004 ($ MILLIONS)
      • TABLE 121: LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY INCLUDING HEARING LOSS, IN FEMALES ($ MILLIONS)
      • TABLE 122: PREMARKET APPROVALS (PMA) FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES
      • TABLE 123: CLINICAL TRIALS FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 124: NEUROSTIMULATION AND HEARING LOSS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
      • Tinnitus
        • TABLE 125: CLINICAL TRIALS FOR TINNITUS-ASSOCIATED NEUROSTIMULATION DEVICES
      • Patents
        • TABLE 126: NEUROSTIMULATION AND TINNITUS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • ADAPTIVE NEUROSTIMULATION THERAPY
      • TABLE 127: CLINICAL TRIALS FOR ADAPTIVE NEUROSTIMULATION TECHNOLOGY

CHAPTER 5 - COMPANY PROFILES

  • ADVANCED BIONICS, LLC
  • ALEVA NEUROTHERAPEUTICS SA
  • ATROTECH OY
  • AUTONOMIC TECHNOLOGIES INC.
  • AVERY BIOMEDICAL DEVICES, INC.
  • BIONESS INC.
  • BIOTRONIK SE & CO.KG
  • BOSTON SCIENTIFIC CORPORATION
  • CERBOMED GMBH
  • COCHLEAR AMERICAS
  • CVRX INC.
  • CYBERONICS, INC.
  • ENTEROMEDICS INC.
  • MED-EL MEDICAL ELECTRONICS
  • MEDTRONIC, INC.
  • NEUROMETRIX INC.
  • NEURONETICS, INC.
  • NEUROPACE INC.
  • NEUROSIGMA
  • NEVRO CORPORATION
  • SECOND SIGHT MEDICAL PRODUCTS, INC.
  • SPINAL MODULATION INC.
  • SPR THERAPEUTICS LLC
  • ST. JUDE MEDICAL
  • UROPLASTY, INC.
  • ZYNEX MEDICAL, INC.

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY THROUGH 2018 ($ MILLIONS)
    • TABLE 1: MARKET SHARE OF CHRONIC PAIN DEVICE MANUFACTURERS ($ MILLIONS)
    • TABLE 2: MARKET SHARE OF CHRONIC PAIN DEVICE MANUFACTURERS ($ MILLIONS)
    • TABLE 3: HEARING LOSS DEVICE GLOBAL MARKET DISTRIBUTION ($ MILLIONS)
    • TABLE 4: MANUFACTURERS OF HEARING LOSS DEVICES MARKET SHARE ($ MILLIONS)
    • TABLE 5: MANUFACTURERS OF OVERACTIVE BLADDER DEVICES MARKET SHARE IN NORTH AMERICA ($ MILLIONS)
    • TABLE 6: MARKET SHARE OF MANUFACTURERS OF EPILEPSY DEVICES ($ MILLIONS)
    • TABLE 7: MARKET SHARE OF MANUFACTURERS OF FOOT DROP DEVICES ($ MILLIONS)
    • TABLE 8: MARKET SHARE OF MANUFACTURERS OF DIABETES/OBESITY DEVICES, 2012 ($ MILLIONS)
    • TABLE 1: PREMARKET APPROVALS (PMA) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 11: PREMARKET NOTIFICATION (510K) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 12: CLINICAL TRIALS FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 13: CLINICAL TRIALS UNDERWAY FOR CHRONIC MIGRAINE-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 14: PREMARKET APPROVALS (PMA) FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 15: CLINICAL TRIALS FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 16: PREMARKET APPROVALS (PMA) FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 17: CLINICAL TRIALS FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 18: AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 19: PREMARKET APPROVALS (PMA) FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 20: CLINICAL TRIALS FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 21: PATENTS FOR NEUROSTIMULATION AND PARKINSON'S APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013 (NUMBER)
    • TABLE 22: PREMARKET APPROVALS (PMA) FOR DYSTONIA-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 23: CLINICAL TRIALS FOR DYSTONIA-ASSOCIATED DEEP NEUROSTIMULATION DEVICES
    • TABLE 24: NEUROSTIMULATION AND DYSTONIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013 (NUMBER)
    • TABLE 25: PREMARKET APPROVALS (PMA) FOR ESSENTIAL TREMOR-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 26: CLINICAL TRIALS FOR ESSENTIAL TREMOR-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
    • TABLE 27: NEUROSTIMULATION AND ESSENTIAL TREMOR PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013 (NUMBER)
    • TABLE 28: DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS (%)
    • TABLE 29: DISTRIBUTION OF RANKINGS FOR EPILEPSY BY GLOBAL REGIONS. (RANK)
    • TABLE 30: GLOBAL PREVALENCE OF EPILEPSY (MILLIONS)
    • TABLE 31: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS IN MALES (%)
    • TABLE 32: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES (%)
    • TABLE 33: GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY (%)
    • TABLE 34: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY (%)
    • TABLE 35: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY (%)
    • TABLE 36: PREMARKET APPROVALS (PMA) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 37: PREMARKET NOTIFICATION (510K) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 38: CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES.
    • TABLE 39: CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED VAGAL NERVE NEUROSTIMULATION DEVICES
    • TABLE 40: NEUROSTIMULATION AND EPILEPSY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013 (NUMBER)
    • TABLE 41: DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP IN GLOBAL MALE POPULATION OF 2004 (%)
    • TABLE 42: DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP IN GLOBAL FEMALE POPULATION OF 2004 (%)
    • TABLE 43: DISTRIBUTION OF RANKINGS FOR SCHIZOPHRENIA BY REGION, 2010 (RANKING)
    • TABLE 44: GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING SCHIZOPHRENIA 2010 (%)
    • TABLE 45: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, 2010 (%)
    • TABLE 46: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, 2010 (%)
    • TABLE 47: CLINICAL TRIALS FOR SCHIZOPHRENIA-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 48: NEUROSTIMULATION AND SCHIZOPHRENIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 49: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)
    • TABLE 50: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER. AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%)
    • TABLE 51: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER, AS A PERCENTAGE OF TOTAL DALYS (%)
    • TABLE 52: DISTRIBUTION OF DALYS FOR OCD IN MALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP, 2006 (%)
    • TABLE 53: DISTRIBUTION OF DALYS FOR OCD IN FEMALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP (%)
    • TABLE 54: CLINICAL TRIALS FOR OCD-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
    • TABLE 55: CLINICAL TRIALS FOR TOURETTE SYNDROME-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
    • TABLE 56: NEUROSTIMULATION AND OCD PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 57: GLOBAL PREVALENCE OF ALZHEIMER'S DISEASE, 2006 (MILLIONS)
    • TABLE 58: RANKING OF MORTALITY DUE TO ALZHEIMER'S IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010 (RANK)
    • TABLE 59: GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S, 2010 (%)
    • TABLE 60: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, 2010 (%)
    • TABLE 61: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, 2010 (%)
    • TABLE 62: CLINICAL TRIALS FOR ALZHEIMER'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 63: NEUROSTIMULATION AND ALZHEIMER'S PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 64: CLINICAL TRIALS FOR ANOREXIA NERVOSA-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES
    • TABLE 65: NEUROSTIMULATION AND ANOREXIA NERVOSA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 66: DISTRIBUTION OF RANKINGS FOR BIPOLAR DISORDER BY GLOBAL REGIONS, 2010
    • TABLE 67: GLOBAL PREVALENCE OF BIPOLAR DISORDER, 2004 (MILLIONS)
    • TABLE 68: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)
    • TABLE 69: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES (%)
    • TABLE 70: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS, 2006 (%)
    • TABLE 71: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, 2010 (%)
    • TABLE 72: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, 2010 (%)
    • TABLE 73: CLINICAL TRIALS FOR BIPOLAR DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 74: NEUROSTIMULATION AND BI-POLAR DISORDER PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 75: DISTRIBUTION OF RANKINGS FOR DEPRESSION BY GLOBAL REGIONS, 2010
    • TABLE 76: GLOBAL PREVALENCE OF DEPRESSION, 2004 (MILLIONS)
    • TABLE 77: GLOBAL DEATHS DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010 (%)
    • TABLE 78: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010 (%)
    • TABLE 79: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010 (%)
    • TABLE 80: PRE-MARKET APPROVALS (PMA) FOR DEPRESSION ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 81: CLINICAL TRIALS FOR DEPRESSION ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 82: NEUROSTIMULATION AND DEPRESSION PATENTS APPLIED AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 83: RANK OF MORTALITY DUE TO STROKE IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010
    • TABLE 84: GLOBAL PREVALENCE OF STROKE BY COUNTRY, 2004 (MILLIONS)
    • TABLE 85: CLINICAL TRIALS FOR STROKE-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 86: NEUROSTIMULATION AND STROKE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 87: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY ETHNICITY IN THE U.S., FROM 1997 TO 2007
    • TABLE 88: CLINICAL TRIALS FOR TRAUMATIC BRAIN INJURY-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 89: NEUROSTIMULATION AND TRAUMATIC BRAIN INJURY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 90: CLINICAL TRIALS FOR HEART FAILURE-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 91: NEUROSTIMULATION AND HEART FAILURE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 92: PRE-MARKET APPROVALS (PMA) FOR GASTRO-ESOPHAGEAL REFLUX DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 93: CLINICAL TRIALS FOR GASTRIC DYSMOTILITY-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 94: NEUROSTIMULATION AND GASTRIC DYSMOTILITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 95: GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP INCLUDING DIABETES IN THE MALE POPULATION OF 2004 (%)
    • TABLE 96: GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP INCLUDING DIABETES, IN THE FEMALE POPULATION OF 2004 (%)
    • TABLE 97: PRE-MARKET APPROVALS (PMA) FOR GASTROPARESIS-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 98: CLINICAL TRIALS FOR GASTRIC DYSMOTILITY ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 99: NEUROSTIMULATION AND GASTROPARESIS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 10: OBESITY IN MALES (>20 YEARS) BY GLOBAL REGION, 2008 (%)
    • TABLE 101: OBESITY IN FEMALES (>20 YEARS) BY GLOBAL REGION, 2008 (%)
    • TABLE 102: DISTRIBUTION OF OBESITY IN U.S. ADULTS (A) AND MALES (B) AS A PERCENTAGE OF TOTAL POPULATION BY AGE GROUP, 2009 TO 2010 (%)
    • TABLE 103: DISTRIBUTION OF OBESITY IN U.S. FEMALES AS A PERCENTAGE OF TOTAL POPULATION, ACCORDING TO AGE GROUP 2009 TO 2010 (%)
    • TABLE 104: PERCENTAGE OF OBESITY AMONG MALES (> 20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008
    • TABLE 105: PERCENTAGE OF OBESITY AMONG FEMALES (> 20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008 (%)
    • TABLE 106: DISTRIBUTION OF OBESITY IN U.S. ADOLESCENTS AND CHILDREN AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 (%)
    • TABLE 107: DISTRIBUTION OF OBESITY IN U.S. BOYS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 (%)
    • TABLE 108: DISTRIBUTION OF OBESITY IN U.S. GIRLS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010 (%)
    • TABLE 109: CLINICAL TRIALS FOR OBESITY-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 110: NEUROSTIMULATION AND OBESITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 111: PRE-MARKET APPROVALS (PMA) FOR OVERACTIVE BLADDER DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 112: CLINICAL TRIALS FOR URINARY INCONTINENCE-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 113: NEUROSTIMULATION AND URINARY INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 114: PREMARKET APPROVALS (PMA) FOR FECAL INCONTINENCE- ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 115: CLINICAL TRIALS FOR FECAL INCONTINENCE ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 116: NEUROSTIMULATION AND FECAL INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 117: DISTRIBUTION OF RANKINGS FOR HEARING LOSS BY REGION, 2010
    • TABLE 118: GLOBAL PREVALENCE OF MODERATE OR GREATER HEARING LOSS DISEASE, 2004 (MILLIONS)
    • TABLE 119: GLOBAL PREVALENCE OF MILD OR GREATER HEARING LOSS DISEASE, 2004 ($ MILLIONS)
    • TABLE 120: LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY, INCLUDING HEARING, LOSS IN MALES, 2004 ($ MILLIONS)
    • TABLE 121: LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY INCLUDING HEARING LOSS, IN FEMALES ($ MILLIONS)
    • TABLE 122: PREMARKET APPROVALS (PMA) FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 123: CLINICAL TRIALS FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 124: NEUROSTIMULATION AND HEARING LOSS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 125: CLINICAL TRIALS FOR TINNITUS-ASSOCIATED NEUROSTIMULATION DEVICES
    • TABLE 126: NEUROSTIMULATION AND TINNITUS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013
    • TABLE 127: CLINICAL TRIALS FOR ADAPTIVE NEUROSTIMULATION TECHNOLOGY

LIST OF FIGURES

  • SUMMARY FIGURE A: DISTRIBUTION OF NEUROSTIMULATION DEVICES BY TYPE OF DISORDER CATEGORY 2012-2018 ($ MILLIONS)
  • SUMMARY FIGURE B: GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY 2012-2018 ($ MILLIONS)
    • FIGURE 1: MARKET SHARE OF CHRONIC PAIN NEUROSTIMULATION DEVICE SALES IN 2012, BY MANUFACTURER (%)
    • FIGURE 2: MARKET SHARE OF HEARING LOSS NEUROSTIMULATION DEVICE SALES IN 2012, BY MANUFACTURER (%)
    • FIGURE 3: SALES DISTRIBUTION OF DIABETES/OBESITY NEUROSTIMULATION DEVICES BY MANUFACTURER, 2012 (%)
    • FIGURE 4: DISTRIBUTION OF CHRONIC BACK PAIN INJURY/ILLNESS REQUIRING DAYS MISSED FROM WORK, BY CONDITION (INCIDENCE RATE)
    • FIGURE 5: DISTRIBUTION OF SPRAINS, STRAINS AND TEARS REQUIRING ABSENCES FROM WORK, BY BODY PARTS INCLUDING BACK (%)
    • FIGURE 6: DISTRIBUTION OF BACK INJURY INCIDENT RATES BY AGE GROUP (INCIDENCE RATE)
    • FIGURE 7: DISTRIBUTION OF INCIDENCE RATES OF SORENESS INCLUDING BACK PAIN, BY AGE GROUP (INCIDENCE RATE)
    • FIGURE 8: DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS INCLUDING MIGRAINE AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS (%)
    • FIGURE 9: DISTRIBUTION OF MIGRAINE INCIDENCE RATES BY AGE GROUP (INCIDENCE RATE)
    • FIGURE 10: GLOBAL PREVALENCE OF PARKINSON'S DISEASE ($ MILLIONS)
    • FIGURE 11: NUMBER OF DEATHS GLOBALLY DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE (%)
    • FIGURE 12: GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE (%)
    • FIGURE 13: GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE (%)
    • FIGURE 14: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS (%)
    • FIGURE 15: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING PARKINSON'S DISEASE AS A PERCENTAGE OF TOTAL DALYS IN MALES (%)
    • FIGURE 16: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES (%)
    • FIGURE 17: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS (%)
    • FIGURE 18: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS (%)
    • FIGURE 19: DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006 (%)
    • FIGURE 20: GLOBAL PREVALENCE OF SCHIZOPHRENIA, 2004 (%)
    • FIGURE 21: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)
    • FIGURE 22: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%)
    • FIGURE 23: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS, 2006 (%)
    • FIGURE 24: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)
    • FIGURE 27: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006 (%)
    • FIGURE 28: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING DEPRESSION, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006 (%)
    • FIGURE 29: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING DEPRESSION, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006 (%)
    • FIGURE 30: DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION AS A PERCENTAGE OF TOTAL DALYS, 2006 (%)
    • FIGURE 31: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION IN MALES AND FEMALES IN THE U.S., 1997 TO 2007 (NUMBER)
    • FIGURE 32: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007 (NUMBER)
    • FIGURE 33: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35-85 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007 (NUMBER)
    • FIGURE 34: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007 (NUMBER)
    • FIGURE 35: TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35 TO 85 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007 (NUMBER)
    • FIGURE 36: DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN MALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005 TO 2008 (%)
    • FIGURE 37: DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN FEMALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005-2008 (%)
    • FIGURE 38: GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP, INCLUDING CARDIOVASCULAR DISEASE, IN THE MALE POPULATION OF 2004 (%)
    • FIGURE 39: GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP, INCLUDING CARDIOVASCULAR DISEASE IN THE FEMALE POPULATION OF 2004 (%)
Back to Top